Navigation Links
Prasco to Market Authorized Generic of ZEGERID®
Date:7/1/2010

CINCINNATI, July 1 /PRNewswire/ -- Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg strengths in the U.S. under the Prasco label.

"We are especially proud to establish this relationship with Santarus and to bring the authorized generic of ZEGERID® to consumers," said Prasco Chief Executive Officer E. Thomas Arington. "With an authorized generic that is manufactured identically to the brand, patients have the benefit of the brand-identical experience at generic savings," stated Arington.

Omeprazole/Sodium Bicarbonate is AB-rated, therapeutically equivalent and substitutable for the brand ZEGERID®. ZEGERID® (omeprazole/sodium bicarbonate) is an immediate-release oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD). These highlights do not include all the information needed to use ZEGERID® safely and effectively. See full prescribing information for ZEGERID® at www.zegerid.com.

ZEGERID® is a registered trademark of Santarus, Inc.

About Prasco

Prasco is a privately-held company located in Cincinnati, Ohio that specializes in selling authorized generics and has partnered with major global pharmaceutical companies to provide patients, pharmacists and customers with generic options that deliver the identical brand experience. The company sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and mail order pharmacies.  For more information, visit www.prasco.com.


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
2. Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
3. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
4. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
7. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
8. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... ... to enhance people’s everyday lives, recently attended the January ECRM Trade Show in ... Science is known for its large range of supplements that keep the body ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
Breaking Medicine News(10 mins):